Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ATRS's Cash to Debt is ranked higher than
93% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.78 vs. ATRS: No Debt )
ATRS' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.80
ATRS's Equity to Asset is ranked higher than
89% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.63 vs. ATRS: 0.80 )
ATRS' s 10-Year Equity to Asset Range
Min: -4.09   Max: 0.94
Current: 0.8

-4.09
0.94
Interest Coverage No Debt
ATRS's Interest Coverage is ranked higher than
87% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. ATRS: No Debt )
ATRS' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 11.09
M-Score: -3.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -101.12
ATRS's Operating margin (%) is ranked lower than
51% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.96 vs. ATRS: -101.12 )
ATRS' s 10-Year Operating margin (%) Range
Min: -1709.11   Max: -26.96
Current: -101.12

-1709.11
-26.96
Net-margin (%) -99.46
ATRS's Net-margin (%) is ranked lower than
51% of the 283 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. ATRS: -99.46 )
ATRS' s 10-Year Net-margin (%) Range
Min: -1728.74   Max: -26.66
Current: -99.46

-1728.74
-26.66
ROE (%) -29.00
ATRS's ROE (%) is ranked higher than
54% of the 279 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. ATRS: -29.00 )
ATRS' s 10-Year ROE (%) Range
Min: -10689.9   Max: -13.2
Current: -29

-10689.9
-13.2
ROA (%) -23.06
ATRS's ROA (%) is ranked higher than
53% of the 286 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. ATRS: -23.06 )
ATRS' s 10-Year ROA (%) Range
Min: -551.1   Max: -10.46
Current: -23.06

-551.1
-10.46
ROC (Joel Greenblatt) (%) -299.91
ATRS's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.38 vs. ATRS: -299.91 )
ATRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3058.04   Max: -203.19
Current: -299.91

-3058.04
-203.19
Revenue Growth (%) 2.20
ATRS's Revenue Growth (%) is ranked higher than
68% of the 248 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. ATRS: 2.20 )
ATRS' s 10-Year Revenue Growth (%) Range
Min: -63.4   Max: 89.8
Current: 2.2

-63.4
89.8
EBITDA Growth (%) 31.70
ATRS's EBITDA Growth (%) is ranked higher than
93% of the 209 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.50 vs. ATRS: 31.70 )
ATRS' s 10-Year EBITDA Growth (%) Range
Min: -41.9   Max: 31.7
Current: 31.7

-41.9
31.7
EPS Growth (%) 31.70
ATRS's EPS Growth (%) is ranked higher than
90% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.80 vs. ATRS: 31.70 )
ATRS' s 10-Year EPS Growth (%) Range
Min: -58.1   Max: 31.7
Current: 31.7

-58.1
31.7
» ATRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ATRS Guru Trades in Q1 2013

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q2 2013

ATRS Guru Trades in Q2 2013

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q3 2013

ATRS Guru Trades in Q3 2013

Jean-Marie Eveillard 20,000 sh (unchged)
» More
Q4 2013

ATRS Guru Trades in Q4 2013

Jean-Marie Eveillard 20,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ATRS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-06-30 Sold Out $2.63 - $3.3 $ 3.071%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Antares Pharma, Inc.

Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET
According to GuruFocus Insider Data, the largest CFO sells during the past week were: Antares Pharma Inc., Denny’s Corporation, Take-Two Interactive Software Inc,, Jarden Corporation and Aceto Corporation. Read more...

Ratios

vs
industry
vs
history
P/B 5.58
ATRS's P/B is ranked lower than
58% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. ATRS: 5.58 )
ATRS' s 10-Year P/B Range
Min: 2.26   Max: 77.5
Current: 5.58

2.26
77.5
P/S 18.06
ATRS's P/S is ranked lower than
78% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. ATRS: 18.06 )
ATRS' s 10-Year P/S Range
Min: 2.42   Max: 36
Current: 18.06

2.42
36

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.77
ATRS's Price/Net Cash is ranked higher than
62% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.40 vs. ATRS: 8.77 )
ATRS' s 10-Year Price/Net Cash Range
Min: 2.06   Max: 85
Current: 8.77

2.06
85
Price/Net Current Asset Value 8.08
ATRS's Price/Net Current Asset Value is ranked higher than
67% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.40 vs. ATRS: 8.08 )
ATRS' s 10-Year Price/Net Current Asset Value Range
Min: 1.91   Max: 56.67
Current: 8.08

1.91
56.67
Price/Tangible Book 5.80
ATRS's Price/Tangible Book is ranked lower than
53% of the 227 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. ATRS: 5.80 )
ATRS' s 10-Year Price/Tangible Book Range
Min: 1.56   Max: 28.33
Current: 5.8

1.56
28.33
Price/Median PS Value 1.44
ATRS's Price/Median PS Value is ranked lower than
53% of the 264 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. ATRS: 1.44 )
ATRS' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 2.46
Current: 1.44

0.08
2.46
Earnings Yield (Greenblatt) 1902.90
ATRS's Earnings Yield (Greenblatt) is ranked higher than
99% of the 226 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. ATRS: 1902.90 )
ATRS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 123.1   Max: 13118.9
Current: 1902.9

123.1
13118.9
Forward Rate of Return (Yacktman) -12.69
ATRS's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.47 vs. ATRS: -12.69 )
ATRS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 40.6   Max: 117.6
Current: -12.69

40.6
117.6

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:MJC.Germany
Antares Pharma, Inc., formerly known as Medi-Ject Corporation, or Medi-Ject, is a specialty pharmaceutical company developing and commercializing self-administered parenteral pharmaceutical products and technologies and topical gel-based products. It develops both subcutaneous and intramuscular injection technology systems including Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. The Company has licensed its reusable needle-free injection device for use with human growth hormone to Teva Pharmaceutical Industries, Ltd., Ferring Pharmaceuticals BV and JCR Pharmaceuticals Co., Ltd., with Teva and Ferring being two of the Company's primary customers. The Company's needle-free injection device is marketed by Teva as the Tjet injector system to administer their 5mg Tev-Tropin brand hGH marketed in the U.S. The Company's needle-free injection device is marketed by Ferring with their 4mg and 10mg hGH formulations as Zomajet 2 Vision and Zomajet Vision X, respectively, in Europe and Asia. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. The Company's product candidate, OTREXUP, is a proprietary combination product comprised of a pre-filled methotrexate syringe and the Company's Medi-Jet self-injection system for the treatment of moderate to severe rheumatoid arthritis. It is also developing Vibex QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency and has conducted a pre-IND meeting with the FDA as part of preparing to initiate clinical development for this product. The Company sells its proprietary reusable needle-free injectors and related disposable products to pharmaceutical partners and through medical product distributors. The Company's competitors include Pfizer, NovoNordisk, Warner-Chilcott, and Novartis.
» More Articles for ATRS

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 

More From Our Partners
Antares Pharma Announces Additional Patent Coverage for OTREXUP Apr 16 2014 - BENZINGA

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide